ICOS-Fc: biotechnological innovation for a healthier aging
A new biotech company focused on an innovative approach for the treatment of cancer and bone-loss related diseases.
Revolutionizing the treatment of bone-loss-related diseases
At NOVAiCOS ImmunoTherapeutics, our mission is to revolutionize the treatment of bone-loss-related diseases, including bone tumors, through an innovative biotechnological platform based on immunotherapy.
We develop cutting-edge therapeutic solutions, leveraging our patented immune-derived compound, ICOS-Fc, the first immunotherapeutic able to simultaneously modulate the immune system and inhibit bone erosion and tumor growth in conditions such as:
-
Osteoporosis
-
Bone Metastases
-
Primary Melanoma
-
Primary Solid Tumors
Driven by science, we are committed to providing safe, modular, reversible and well-tolerated therapies, redefining the future of bone health and improving patients’ quality of life.
Our bioengineered platform
ICOS-Fc targets the ICOS/ICOSL immune pathway to block tumor progression, reduce osteolysis and improve patients’ quality of life.
Discover ICOS-Fc
Stay updated with the latest NOVAiCOS news
Patents, milestones, events and corporate updates.
All news
